ART Guidelines

ART Guidelines


Please review the disclaimer before proceeding with these guidelines

×

×





  • ×
  • ABBREVIATIONS
    /r ritonavir-boosted
    3TC lamivudine
    ABC abacavir
    ADR adverse drug reaction
    AKI acute kidney injury
    ALT alanine transaminase
    ANC antenatal care
    ART antiretroviral therapy
    ARV antiretroviral
    AST aspartate transaminase
    ATV atazanavir
    ATV/r ritonavir-boosted atazanavir
    AZT zidovudine
    bd twice daily
    CD4+ cluster of differentiation 4
    CM cryptococcal meningitis
    CNS central nervous system
    CrAg cryptococcal antigen
    CrCl creatinine clearance rate
    CSF cerebrospinal fluid
    CTX cotrimoxazole
    d4T stavudine
    ddI didanosine
    DILI drug-induced liver injury
    DNA deoxyribonucleic acid
    DRV darunavir
    DRV/r ritonavir-boosted darunavir
    DTG dolutegravir
    eGFR estimated glomerular filtration rate
    ELISA enzyme-linked immunosorbent assay
    ETR etravirine
    FBC full blood count
    FTC emtricitabine
    GI gastrointestinal
    Hb haemoglobin
    HBsAg hepatitis B surface antigen
    HBV hepatitis B virus
    HIV human immunodeficiency virus
    ICU intensive care unit
    INH isoniazid
    INR international normalised ratio
    InSTI integrase strand transfer inhibitor
    IPT isoniazid preventive therapy
    IRIS immune reconstitution inflammatory syndrome
    LAM lipoarabinomannan
    LDL-C low-density lipoprotein cholesterol
    LFT liver function test
    LP lumbar puncture
    LPV lopinavir
    LPV/r ritonavir-boosted lopinavir
    MDRD modification of diet in renal disease
    MTCT mother-to-child transmission of HIV
    MVC maraviroc
    NGT nasogastric tube
    NNRTI non-nucleoside reverse transcriptase inhibitor
    NRTI nucleoside reverse transcriptase inhibitor
    NTDs neural-tube defects
    NtRTI nucleotide reverse transcriptase inhibitor
    NVP nevirapine
    OI opportunistic infection
    PAS p-aminosalicylic acid
    PCR polymerase chain reaction
    PI protease inhibitor
    PI/r ritonavir-boosted protease inhibitor
    PMTCT prevention of mother-to-child transmission of HIV
    PPIs proton pump inhibitors
    PrEP pre-exposure prophylaxis
    QTc corrected QT interval
    RAL raltegravir
    RCTs randomised controlled trials
    RIF rifampicin
    RFB rifabutin
    RNA ribonucleic acid
    RPV rilpivirine
    RTV or /r ritonavir
    sCr serum creatinine
    sCrAg serum cryptococcal antigen
    TAF tenofovir alafenamide
    TAM thymidine analogue mutation
    TB tuberculosis
    TB-IRIS tuberculosis immune reconstitution inflammatory syndrome
    TBM tuberculosis meningitis
    TC total cholesterol
    TDF tenofovir disoproxil fumarate
    TG triglycerides
    TST tuberculin skin test
    UDP uridine 5’-diphospho
    ULN upper limit of normal
    VL viral load
    WHO World Health Organization
    WOCP women of childbearing potential








    Liver Disease
    Antiretroviral drug dose adjustment in liver impairment
            Key points
     
    • There is no single blood test for accurate quantification of liver impairment.
    • Child-Pugh class C may require dose adjustment for some ARV drugs.
    • The combination of TDF + 3TC (or FTC) + DTG (or RAL) is regarded as least hepatotoxic.

    Table 23 outlines dose adjustments for the relevant ART drugs in patients with Child-Pugh class C liver impairment.

    Tip: To best view this table, zoom in or rotate your mobile device into landscape orientation.

    TABLE 23: Prescribing antiretroviral therapy in liver impairment.
    Class Drug Prescribing notes
    NRTI TDF No dose adjustment necessary.
    3TC No dose adjustment necessary.
    FTC No dose adjustment necessary.
    AZT Decrease dose by 50% or double dosage interval in significant liver disease.
    ABC Reduce adult dose to 200 mg twice daily in significant liver disease.
    Contraindicated in severe liver disease.
    InSTI DTG No data on recommendation for those with severe liver disease (Child-Pugh class C).
    RAL No dose adjustment necessary.
    PI DRV Use with caution or avoid in significant liver disease.
    ATV Avoid in severe liver disease.
    LPV/r LPV is highly metabolised in the liver and concentrations may be increased in patients with hepatic impairment. Therapeutic drug monitoring should be done if available.
    NNRTI EFV Not recommended in severe liver disease.
    ETR Use with caution in severe liver disease.
    RPV Use with caution in severe liver disease (Child-Pugh class C) – dose recommendation not established.
    CCR5 blocker MVC Concentrations likely to be increased with liver impairment.

    3TC, lamivudine; ABC, abacavir; ATV, atazanavir; ARVs, antiretrovirals; AZT, zidovudine; CCR5, C-C chemokine receptor type 5; DTG, dolutegravir; DRV, darunavir; EFV, efavirenz; ETR, etravirine; FTC, emtricitabine; InSTI, integrase strand transfer inhibitor; LPV, lopinavir; LPV/r, ritonavir-boosted lopinavir; MVC, maraviroc; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitors; PI, protease inhibitor; RAL, raltegravir; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate.


    Hepatitis B virus/HIV co-infection
            Key points
     
    • All HIV-infected individuals should be screened for active hepatitis B virus (HBV) – hepatitis B surface antigen (HBsAg) screening is an appropriate test.
    • The HBV VL correlates with disease progression and is used to monitor anti-HBV therapy.
    • All children and adults eligible for HBV vaccination should be vaccinated.
    • ART drugs with anti-HBV activity are TDF + 3TC (or FTC).
    • For all HIV-infected HBsAg-positive patients, the ART regimen should include TDF + 3TC (or FTC).
    • Using 3TC without TDF to treat HBV/HIV co-infection leads to HBV resistance in 80–90% of patients after 5 years of treatment.
    • Interruption of TDF and/or 3TC (or FTC) has been associated with flares of life-threatening hepatitis in patients with HBV in case reports.
    • Adjust dosing frequency of TDF in patients with HBV infection and renal dysfunction; if renal function is severe or deteriorates with TDF, then 3TC monotherapy or other drugs with anti-HBV activity should be considered.

    HBV is a common co-infection with HIV in southern Africa, with significant implications for progression to cirrhosis, as well as for treatment options. Access to vaccination, laboratory resources and treatment options is limited to some extent in southern African countries, and the recommendations below should each be considered in the light of the local context.

    HBV/HIV co-infection is associated with:

    • an increased risk of chronic liver disease
    • a higher HBV VL
    • diminished responses to HBV vaccine
    • an increased risk of drug-induced hepatotoxicity
    • a flare of hepatitis within 3 months of commencing ART (due to HBV-related IRIS, which is difficult to differentiate from drug hepatotoxicity).
       

    Drugs directed against HBV that have no/minimal anti-HIV activity (e.g. entecavir and telbivudine) are largely unavailable or extremely expensive in our region. Instead, it is usually necessary to use ART drugs that also have anti-HBV activity: TDF + 3TC (or FTC). As with HIV, these drugs suppress HBV, but do not eradicate it. Effective treatment prevents or slows progression to cirrhosis. For all HIV-infected hepatitis B surface antigen (HBsAg)-positive patients, the ART regimen should include TDF + 3TC (or FTC). Using 3TC without including TDF leads to the development of HBV resistance in 80–90% of patients after 5 years of treatment. If a patient meets the criteria for switching to a second-line ART regimen (to treat HIV), then this combination – TDF + 3TC (or FTC) – should be continued to suppress HBV infection, as interruption of TDF and/or 3TC (or FTC) has been associated with flares of life-threatening hepatitis in case reports. The second-line ART regimen should be shaped around these two drugs.

    In patients with HBV and renal dysfunction, the use of TDF may be considered with dosing frequency adjustment based on CrCl (Table 24) and more frequent creatinine monitoring. If renal dysfunction is severe or renal function deteriorates with TDF, then 3TC monotherapy or other drugs with anti-HBV activity should be considered.
     

    Tip: To best view this table, zoom in or rotate your mobile device into landscape orientation.

    TABLE 24: Suggested tenofovir disoproxil fumarate dose adjustment in patients with hepatitis B and renal dysfunction.
    eGFR
    (mL/min/1.73 m2)
    Suggested dose of TDF
    ≥ 50 Usual dose
    30–49 300 mg every 48 hours
    10–29 300 mg every 72–96 hours
    < 10 Avoid (consider 3TC monotherapy, or other drugs with anti-HBV activity)
    Haemodialysis 300 mg every week (dose after dialysis on dialysis days)

    3TC, lamivudine; eGFR, estimated glomerular filtration rate; HBV, hepatitis B virus; TDF, tenofovir disoproxil fumarate.


    Common pitfall: Not continuing with TDF + 3TC (or FTC) combination when switching to second-line ART. The second-line ART regimen should be shaped around these two drugs.
    Common pitfall: Using 3TC without including TDF in the treatment of HIV/HBV co-infected patients.